(UroToday.com) In this study by Evan Gross and colleagues, the authors explore the survival outcomes of patients with metastatic renal cell carcinoma (mRCC) who received Immune Checkpoint Inhibitor Therapy (ICI) with or without cytoreductive nephrectomy (CN). With the role of CN increasingly being re-evaluated, especially in the context of CARMENA and SURTIME, the authors specifically wanted to focus on the ICI era of mRCC treatment. In this retrospective review of patients diagnosed with mRCC from 2000-2020 at two institutions (Seattle Cancer Care Alliance and Ohio State University), they explored the association between CN and OS. Median follow-up in survivors was 28.4 months.